2018
DOI: 10.1055/s-0038-1644988
|View full text |Cite
|
Sign up to set email alerts
|

Modelling the progression of a preleukemic stage to overt leukemia in children with Down syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…It was recently demonstrated that GM-CSF/CSF2 enhances survival in Down syndrome transient abnormal myelopoiesis (TAM), suggesting a growth advantage for ML-DS under GM-CSF/CSF2-rich conditions. 35 When CMK cells were injected into GS larvae, xenografts demonstrated increased cell proliferation at 3 dpi compared to casper controls ( Figure 2C , D). Strikingly, this was preceded by a sudden decrease in the number of CMK cells in both control and transgenic larvae at 2 dpi ( Figure 2D ).…”
Section: Resultsmentioning
confidence: 97%
“…It was recently demonstrated that GM-CSF/CSF2 enhances survival in Down syndrome transient abnormal myelopoiesis (TAM), suggesting a growth advantage for ML-DS under GM-CSF/CSF2-rich conditions. 35 When CMK cells were injected into GS larvae, xenografts demonstrated increased cell proliferation at 3 dpi compared to casper controls ( Figure 2C , D). Strikingly, this was preceded by a sudden decrease in the number of CMK cells in both control and transgenic larvae at 2 dpi ( Figure 2D ).…”
Section: Resultsmentioning
confidence: 97%